Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Multicomponent Intervention Study- Blood Donors With High Cholesterol
Recruiting
The purpose and objective of this study is to improve cholesterol treatment among blood donors with FH (Familial Hypercholesterolemia).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/02/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Lipid Metabolism Disorder
A Study of NB004 As Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors
Recruiting
This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Recruiting
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/01/2025
Locations: Baylor Scott and White Research, Temple, Texas
Conditions: C3G
Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.
Recruiting
Gemini is being evaluated in a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney disease. Pharmacokinetics will be evaluated and measurements of the effect of Gemini on pharmacodynamic activity will be measured to assess changes in potential pharmacodynamic markers.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/28/2025
Locations: Clinical Advance Center, PLLC, San Antonio, Texas
Conditions: Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer
Recruiting
This clinical trial compares the use of a new screening tool designed to evaluate patients' information needs, preferences, and illness understanding to the usual care to improve illness understanding in patients with lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or for which no curative treatment is currently available (incurable). Goal concordant care is a model of care that aligns a patient's medical care with their values, pre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Carcinoma, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8
Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health
Recruiting
To learn more about social and financial factors that may influence outcomes of TCT treatment at MD Anderson.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Transplant and Cell Therapy
Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Recruiting
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
Recruiting
This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Advanced Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future ca... Read More
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
02/28/2025
Locations: UT Southwestern, Dallas, Texas
Conditions: Chronic Kidney Disease
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Dallas, Texas
Conditions: Neoplasms
Longitudinal Study of the Porphyrias
Recruiting
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Gender:
ALL
Ages:
1 minute and above
Trial Updated:
02/28/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Acute Porphyrias, Cutaneous Porphyrias
Arlington Aging Study
Recruiting
The goal of this observational study is to learn about the mechanisms causing functional decline with age, using exercise science, neuroscience, and remote monitoring. Specific aims include: Aim 1: Advance knowledge of the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability. Aim 2: Determine the effects of personal and societal factors on aging. Aim 3: Examine the influence of racial/ethnic and sex differences on the biology of aging and it... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/27/2025
Locations: University of Texas Arlington, Arlington, Texas
Conditions: Aging